Literature DB >> 14572538

Therapeutic vaccines against infectious diseases.

Philippe Moingeon1, Jeffrey Almond, Michel de Wilde.   

Abstract

Therapeutic vaccines against chronic infectious diseases aim at eliciting broad humoral and cellular immune responses against multiple target antigens. Importantly, the development of such vaccines will help to establish surrogate markers of protection in humans and thus will augment the subsequent development of efficient prophylactic vaccines. A combination of synthetic small-molecule drugs and immunotherapeutics is likely to represent a powerful means of controlling chronic infections in the future. Challenges faced in developing therapeutic vaccines include the following: first, overcoming the potential impairment of immune responses due to established infection; second, optimizing schedules of vaccine administration in combination with standard of care chemotherapy; and third, defining what biological and immunological read-outs should be used to infer vaccine efficacy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14572538     DOI: 10.1016/j.mib.2003.08.002

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  6 in total

1.  A super TLR agonist to improve efficacy of dendritic cell vaccine in induction of anti-HCV immunity.

Authors:  Bangxing Hong; Sung-Hyung Lee; Xiao-Tong Song; Lindsey Jones; Keigo Machida; Xue F Huang; Si-Yi Chen
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

2.  Ubiquitin conjugation of hepatitis B virus core antigen DNA vaccine leads to enhanced cell-mediated immune response in BALB/c mice.

Authors:  Jian-Hua Chen; Yong-Sheng Yu; Hong-Hong Liu; Xiao-Hua Chen; Min Xi; Guo-Qing Zang; Zheng-Hao Tang
Journal:  Hepat Mon       Date:  2011-08       Impact factor: 0.660

3.  Detrimental Effect of Fungal 60-kDa Heat Shock Protein on Experimental Paracoccidioides brasiliensis Infection.

Authors:  Fabrício Freitas Fernandes; Leandro Licursi de Oliveira; Taise Natali Landgraf; Gabriela Peron; Marcelo Vieira Costa; Arlete A M Coelho-Castelo; Vânia L D Bonato; Maria-Cristina Roque-Barreira; Ademilson Panunto-Castelo
Journal:  PLoS One       Date:  2016-09-06       Impact factor: 3.240

4.  Prevention and Immunotherapy of Secondary Murine Alveolar Echinococcosis Employing Recombinant EmP29 Antigen.

Authors:  Ghalia Boubaker; Andrew Hemphill; Cristina Olivia Huber; Markus Spiliotis; Hamouda Babba; Bruno Gottstein
Journal:  PLoS Negl Trop Dis       Date:  2015-06-08

5.  Vaccine Development Against COVID-19 Prior to Pandemic Outbreaks, Using in vitro Evolution and Reverse Genetics.

Authors:  Hatem Zayed
Journal:  Front Immunol       Date:  2020-08-14       Impact factor: 7.561

Review 6.  Mesenchymal Stem Cell-Derived Exosome Therapy of Microbial Diseases: From Bench to Bed.

Authors:  Xiaolan Wu; Shanshan Jin; Chengye Ding; Yu Wang; Danqing He; Yan Liu
Journal:  Front Microbiol       Date:  2022-01-03       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.